{
  "question_stem": {
    "en": "A 22-year-old man comes to the office due to a 6-month history of difficulty breathing and chest discomfort on exertion. He also reports intermittent palpitations. The patient's only other medical condition is major depression. Temperature is 37 C (98.6 F), blood pressure is 120/80 mm Hg, pulse is 82/min, and respirations are 15/min. Pulse oximetry on room air shows an oxygen saturation of 98%. BMI is 24 kg/m2. The lungs are clear on auscultation. Cardiac examination reveals a prominent left ventricular impulse on palpation, an S4, and a faint systolic murmur at the left sternal border that accentuates during the strain phase of the Valsalva maneuver.",
    "zh": "一名22岁男性因6个月来劳力性呼吸困难和胸部不适就诊。他还自诉间歇性心悸。患者唯一其他的病史是重度抑郁症。体温37°C（98.6°F），血压120/80 mmHg，脉搏82次/分，呼吸15次/分。在常温空气中进行脉搏血氧饱和度显示为98%。BMI为24 kg/m2。肺部听诊清澈。心脏检查显示，触诊时左心室搏动明显，S4，以及在Valsalva动作的屏气阶段加重的左胸骨旁轻微收缩期杂音。"
  },
  "question": {
    "en": "Verapamil therapy would most likely improve this patient's dyspnea through which of the following mechanisms?",
    "zh": "维拉帕米治疗最有可能通过以下哪种机制改善该患者的呼吸困难？"
  },
  "options": {
    "A": {
      "en": "Decrease in left ventricular afterload",
      "zh": "降低左心室后负荷"
    },
    "B": {
      "en": "Decrease in left ventricular end-diastolic cavity size",
      "zh": "降低左心室舒张末期腔室大小"
    },
    "C": {
      "en": "Increase in atrioventricular conduction velocity",
      "zh": "增加房室传导速度"
    },
    "D": {
      "en": "Increase in left ventricular diastolic filling time",
      "zh": "增加左心室舒张充盈时间"
    },
    "E": {
      "en": "Increase in myocardial contraction velocity",
      "zh": "增加心肌收缩速度"
    }
  },
  "correct_answer": "D",
  "explanation": {
    "en": "A systolic murmur at the left sternal border that increases in intensity with maneuvers that decrease left ventricular (LV) blood volume is characteristic of HYPERTROPHIC CARDIOMYOPATHY (HCM). The murmur is caused by dynamic LV outflow tract obstruction that worsens with relatively low LV blood volume and improves with relatively high LV blood volume. Other common physical examination findings include an S4 (caused by LV wall-thickening) and prominent LV impulse. Patients may be asymptomatic or have palpitations and/or exertional symptoms, including dyspnea, chest pain, lightheadedness, and syncope.\n\nPharmacologic management of HCM focuses on maintaining relatively high LV blood volume throughout the cardiac cycle, which minimizes LV outflow tract obstruction and associated symptoms. This is best accomplished via 2 mechanisms:\n\n*   Negative chronotropy (ie, reduced heart rate), which lengthens diastolic filling time to increase LV end-diastolic volume (ie, preload)\n*   Negative inotropy (ie, reduced LV contractility), which decreases the amount of blood ejected during ventricular systole (ie, increased end-systolic volume)\n\nBeta blockers and nondihydropyridine calcium channel blockers (eg, verapamil) are used in HCM to provide negative chronotropy and inotropy and reduce symptoms related to outflow tract obstruction.\n\n(Choice A) Decreased LV afterload is primarily caused by arterial dilators (eg, ACE inhibitors, dihydropyridine calcium channel blockers such as amlodipine) and is detrimental in HCM as it reduces LV blood volume to worsen LVOT obstruction. Verapamil has no significant vasodilatory effect on systemic vessels.\n\n(Choices B and C) The negative chronotropy of verapamil decreases atrioventricular conduction velocity to lengthen diastolic filling time and increase LV end-diastolic cavity size. An increase in atrioventricular conduction velocity (eg, as occurs with exercise) tends to decrease LV end-diastolic cavity size and worsen LV outflow tract obstruction.\n\n(Choice E) The negative inotropy of verapamil decreases myocardial contraction velocity. Increased contraction velocity can worsen LV outflow tract obstruction by reducing end-systolic volume.\n\nEducational objective:\nHypertrophic cardiomyopathy commonly involves dynamic left ventricular (LV) outflow tract obstruction that worsens with decreased LV blood volume and improves with increased LV blood volume. Nondihydropyridine calcium channel blockers (eg, verapamil) decrease heart rate (ie, negative chronotropy) and LV contractility (ie, negative inotropy) to increase LV blood volume, reduce LV outflow tract obstruction, and improve symptoms.",
    "zh": "在左胸骨旁，随着降低左心室（LV）血容量的动作，强度增加的收缩期杂音是肥厚型心肌病（HCM）的特征。这种杂音是由动态的LV流出道梗阻引起的，当LV血容量相对较低时会加重，而当LV血容量相对较高时会改善。其他常见的体格检查结果包括S4（由LV壁增厚引起）和明显的LV搏动。患者可能无症状，或有心悸和/或劳力性症状，包括呼吸困难、胸痛、头晕和晕厥。\n\nHCM的药物治疗侧重于在整个心动周期中维持相对较高的LV血容量，从而最大限度地减少LV流出道梗阻和相关症状。这最好通过两种机制实现：\n\n*   负性频率（即降低心率），这会延长舒张充盈时间，以增加LV舒张末期容量（即，前负荷）\n*   负性肌力（即降低LV收缩力），这会减少心室收缩期射出的血量（即，增加收缩末期容量）\n\nβ受体阻滞剂和非二氢吡啶类钙通道阻滞剂（例如，维拉帕米）用于HCM，以提供负性频率和肌力，并减轻与流出道梗阻相关的症状。\n\n（选项A）降低LV后负荷主要由动脉扩张剂引起（例如，ACE抑制剂、二氢吡啶类钙通道阻滞剂，如氨氯地平），这在HCM中是有害的，因为它会降低LV血容量，使LVOT梗阻恶化。维拉帕米对全身血管没有明显的舒张作用。\n\n（选项B和C）维拉帕米的负性频率降低了房室传导速度，以延长舒张充盈时间并增加LV舒张末期腔室大小。房室传导速度的增加（例如，随着运动而发生）倾向于降低LV舒张末期腔室大小并加重LV流出道梗阻。\n\n（选项E）维拉帕米的负性肌力降低了心肌收缩速度。增加的收缩速度会通过减少收缩末期容量来加重LV流出道梗阻。\n\n教育目标：\n肥厚型心肌病通常涉及动态左心室（LV）流出道梗阻，当LV血容量降低时会恶化，当LV血容量增加时会改善。非二氢吡啶类钙通道阻滞剂（例如，维拉帕米）可降低心率（即负性频率）和LV收缩力（即负性肌力），从而增加LV血容量，减少LV流出道梗阻，并改善症状。"
  },
  "summary": {
    "en": "This question tests knowledge of hypertrophic cardiomyopathy (HCM), its pathophysiology related to left ventricular outflow tract (LVOT) obstruction, and the mechanism of action of verapamil in managing HCM symptoms. Verapamil, a non-dihydropyridine calcium channel blocker, improves dyspnea in HCM by increasing left ventricular diastolic filling time through negative chronotropy and inotropy, thereby reducing LVOT obstruction. \n\nTo solve this question, recognize the clinical presentation suggestive of HCM (exertional dyspnea, systolic murmur increasing with Valsalva), understand the underlying mechanism of LVOT obstruction, and recall the pharmacologic effects of verapamil in HCM management.",
    "zh": "这个问题考察了对肥厚型心肌病（HCM）的了解，其与左心室流出道（LVOT）梗阻相关的病理生理学，以及维拉帕米在管理HCM症状中的作用机制。维拉帕米，一种非二氢吡啶类钙通道阻滞剂，通过负性频率和肌力增加左心室舒张充盈时间，从而减少LVOT梗阻，改善HCM患者的呼吸困难。\n\n要解决这个问题，需要识别提示HCM的临床表现（劳力性呼吸困难，Valsalva动作时增强的收缩期杂音），了解LVOT梗阻的潜在机制，并回忆维拉帕米在HCM管理中的药理作用。"
  },
  "tags": "Hypertrophic cardiomyopathy; Cardiology; Verapamil; Left ventricular outflow tract obstruction; Diastolic dysfunction; Negative chronotropy; Negative inotropy; Calcium channel blockers; Cardiac murmur",
  "category": "CVS",
  "question_id": "22787",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\CVS 23\\22787",
  "extracted_at": "2025-11-05T12:11:47.991569",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T17:28:48.400900",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}